Compare SNOA & ITOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNOA | ITOC |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 7.0M |
| IPO Year | 2006 | N/A |
| Metric | SNOA | ITOC |
|---|---|---|
| Price | $1.12 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 93.8K | ★ 211.7K |
| Earning Date | 02-10-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,288,000.00 | N/A |
| Revenue This Year | $23.00 | N/A |
| Revenue Next Year | $24.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.19 | N/A |
| 52 Week Low | $1.80 | $0.25 |
| 52 Week High | $6.92 | $0.65 |
| Indicator | SNOA | ITOC |
|---|---|---|
| Relative Strength Index (RSI) | 26.78 | 61.33 |
| Support Level | N/A | $0.32 |
| Resistance Level | $3.84 | $0.49 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 14.19 | 95.75 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors.